Blog

25 February 2026

Understanding the Long-Term Challenges of Hidradenitis Suppurativa

Discover the long-term challenges of hidradenitis suppurativa (HS) from expert Thrasyvoulos Tzellos, MD. Learn about its progressive nature and patient...
Read more
Understanding the Long-Term Challenges of Hidradenitis Suppurativa
Remibrutinib Achieves Key Milestone in Phase 3 Trial for CIndU

Remibrutinib Achieves Key Milestone in Phase 3 Trial for CIndU

Discover how remibrutinib achieved a key milestone in its phase 3 trial for chronic inducible urticaria (CIndU), setting the stage...
24 02 2026
Read more
Revolutionizing Acne Treatment: Denifanstat Targets Sebum Production

Revolutionizing Acne Treatment: Denifanstat Targets Sebum Production

Discover how denifanstat is revolutionizing acne treatment by targeting sebum production. Learn about this innovative therapy that offers a new...
23 02 2026
Read more
Alphyn Biologics Launches Phase 2 Trial for Zabalafin Hydrogel Treatment

Alphyn Biologics Launches Phase 2 Trial for Zabalafin Hydrogel Treatment

Alphyn Biologics announces a Phase 2 trial for Zabalafin Hydrogel, targeting molluscum contagiosum in pediatric patients. Discover this innovative treatment's...
23 02 2026
Read more
Brepocitinib Shows Promising Phase 2 Results for Rare Skin Disease

Brepocitinib Shows Promising Phase 2 Results for Rare Skin Disease

Discover the promising Phase 2 results of brepocitinib for cutaneous sarcoidosis, showcasing impressive efficacy and safety in a rare skin...
23 02 2026
Read more
Navigating Systemic Mastocytosis: A Patient’s Journey to Diagnosis and Care

Navigating Systemic Mastocytosis: A Patient’s Journey to Diagnosis and Care

Discover Suki Tipp's journey through systemic mastocytosis, from misdiagnosis to effective care. Learn the importance of early recognition in this...
22 02 2026
Read more
New Study Confirms 487-GEP for Choosing JAK Inhibitors in Severe AD

New Study Confirms 487-GEP for Choosing JAK Inhibitors in Severe AD

Discover how the new 487-GEP test enhances JAK inhibitor selection for severe atopic dermatitis. Learn about its impact on treatment...
22 02 2026
Read more
Exploring BDCA2 Inhibition: A New Hope for Cutaneous Lupus Treatment

Exploring BDCA2 Inhibition: A New Hope for Cutaneous Lupus Treatment

Discover the potential of BDCA2 inhibition in treating cutaneous lupus erythematosus with litifilimab. Explore new therapeutic advancements and patient insights.
21 02 2026
Read more
Understanding Short-Term Systemic Corticosteroids in Atopic Dermatitis Care

Understanding Short-Term Systemic Corticosteroids in Atopic Dermatitis Care

Discover essential insights on short-term systemic corticosteroids in atopic dermatitis care. Learn about risks, benefits, and expert guidance for effective...
21 02 2026
Read more